Introduction to the main efficacy and clinical therapeutic effects of ibrutinib

Ibrutinib (also known as ibrutinib, English name: Ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor. It is a targeted therapy drug and is mainly used to treat a variety of malignant tumors derived from BB cells. It inhibits the B cell receptor signaling pathway by irreversibly binding to BTK, thereby inhibiting the proliferation and survival of abnormal B cells. It is one of the core drugs for diseases such as B-cell leukemia (CLL), mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinemia (WM).

In chronic lymphocytic leukemia (CLL), ibrutinib is widely used in newly diagnosed and relapsed cases/Treatment of refractory patients, especially for high-risk groups with chromosome 17p deletions or TP53 mutations. Studies have shown that ibrutinib can significantly prolong progression-free survival (PFS) and overall survival (OS). Compared with traditional chemotherapy regimens, ibrutinib is convenient to take orally and has milder adverse reactions. It is currently an important choice for first-line treatment of CLL.

Ibrutinib also has good efficacy in mantle cell lymphoma (MCL). For patients with relapsed or refractory MCL, ibrutinib can quickly control the disease, and some patients have significant tumor shrinkage or even complete remission after treatment. Its mechanism of action not only inhibits tumor growth, but also improves the quality of life of some patients. It is especially suitable for elderly or patients with underlying diseases.

In addition, ibrutinib is also used to treat rare B cell lymphomas such as Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), and the efficacy is equally stable. With the deepening of research, the indications of ibrutinib are constantly expanding, and some studies are exploring the prospects of using it in combination with other targeted drugs or immunotherapy, showing broader clinical application potential.

Reference materials:https://www.drugs.com